Anterra Capital — 2016 Investments

1 investments dated 2016 · listed companies and verified rows first · show all

Caribou Biosciencescariboubio.com in 𝕏NASDAQ: CRBUSeries B · May 2016 · $30M

Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform.

BiotechMedical DevicesBerkeley, US

Jennifer Doudna(Co-founder)Rachel Haurwitz(President and Chief Executive Officer, Co-founder)inMartin Jinek(Co-founder)Andrew May(Executive Officer)

Board Jenny Rooke(Director)in Robert Weisskoff(Director)in

Co-investorsAliment Capital Avego BioScience Capital F-Prime Capital IA Seed Ventures Mission Bay Capital Mission Biocapital +2 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.